[A19-11] Nivolumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
|2019-05-15||Executive summary of dossier assessment (German version)||101 kB|
|2019-05-15||Dossier assessment (German version)||921 kB|
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2019-08-15 A G-BA decision was published.